Head-to-head · WeighScore
telos rx vs Gala Health
The verdict
Gala Health takes it — 86/100 to 85/100, but only just.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A low-entry compounded tirzepatide program (from $149 microdose) that reaches all 50 states and keeps a brand-name Ozempic path open — a rare combination this far up the value tier. telos rx is close behind and may still be the better fit — see the factor split below.
Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | telos rx | Gala Health |
|---|---|---|
| WeighScore | 85/100 | 86/100 |
| Grade | B | B |
| Scorecard rank | #15 | #8 |
| Semaglutide | From $49/mo (annual) | Not disclosed |
| Tirzepatide | $99/mo (annual) | $179/mo |
| Coverage | Not publicly listed | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #15 · B
Strengths
- Deep published catalog — sema, tirz, PT-141, intranasal NAD+, recovery/GH peptides, GHK-Cu, Dihexa, HRT
- Needle-free and oral GLP-1 options, not injection-only
- LegitScript-certified and HIPAA, with US providers and pharmacies, HSA/FSA and free shipping
- Low GLP-1 entry — from $49/mo microdosed on an annual plan
Where it loses points
- Everything is compounded and not FDA-approved, including the peptides
- Pricing is opaque outside GLP-1 and the lowest rates require annual lock-in
- No named clinicians and thin third-party reviews
- Several research-grade peptides carry limited clinical evidence
Graded #8 · B
Strengths
- Low compounded entry — tirzepatide $179/mo, microdose from $149, 3-month plans from $199
- Available in all 50 states
- Keeps a brand-name path open (Ozempic listed at $1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet
- Newer operator (Gala GLP-1 by AI Coaching Inc) with a shorter public record
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 34 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.